- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
IVVD
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
Invivyd Inc. · Healthcare · Biotechnology
Latest close
0.54 USD
-12.5%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -61.3% below the Trend Line and sits at 2.0% of its 52-week range. The latest completed week returned -12.5%, after a -40.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 58/100 conviction, while the latest news-sentiment score is 47/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.
Setup score
16
out of 100
Latest Close
0.54 USD
31 Jul 2026
1W Return
-12.5%
latest completed week
4W Return
-40.1%
short-term follow-through
12W Return
-64.3%
quarterly tape
Trend Breadth
42.3%
22 of 52 weeks active
Volume Ratio
0.8x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-12.5%
Latest completed week; four-week move -40.1%.
Indicator stack
23/22
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 42.06%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
58/100 conviction; expected move 32.7%.
News sentiment
47/100
56 relevant articles in the latest sentiment read.
Event risk
11d
Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -61.3% below the Trend Line and sits at 2.0% of its 52-week range. The latest completed week returned -12.5%, after a -40.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0412-week average 0.11
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.04Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -40.1% over four weeks, -64.3% over 12 weeks, and -26.9% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year22
Trend breadth42.3%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.25Latest activity-pressure read.
Pressure change-71.3%Four-week change in activity pressure.
Leadership-68.10Latest relative-leadership reading.
RS change-38.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 76%
Model confidence 73%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength80/100Blend of value, momentum, and quality. Underlying universe rank 21; rank 1 is best.
Value65/100Relative valuation strength. Underlying universe rank 36; rank 1 is best.
Quality63/100Profitability and accounting quality. Underlying universe rank 38; rank 1 is best.
Momentum65/100Medium-term price momentum. Underlying universe rank 36; rank 1 is best.
Growth65/100Revenue and earnings growth. Underlying universe rank 36; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- - Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 92.0% Gross profit retained from each unit of revenue.
- Operating margin
- -138.9% Operating profit retained from revenue.
- Free-cash-flow margin
- -139.6% Free cash flow generated from revenue.
- Return on invested capital
- -211.5% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 52.3% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 2/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- - Net share repurchases relative to market value.
- Shareholder yield
- - Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.3x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
IVVD shows volatility options pressure with a 58/100 conviction score, put-call volume ratio of 0.03, expected move of 32.7%, and Sharemaestro trend signal inactive.
Conviction58/100
Expected move32.7%
Put/call volume0.03
Insider activity6 / 0
6 acquisitions and 0 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment47/100
Weighted news tone is neutral across 56 relevant articles.
8 positive · 34 neutral · 14 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move32.7%Nearest-chain priced movement where available.
52-week drawdown-82.6%Distance below the 52-week high.
13-week volatility12.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher7 of 2619 weeks finished lower.
Best week+37.5%Week of 10 Apr.
Worst week-25.2%Week of 12 Jun.
Latest week-12.5%Week of 31 Jul.
Shape of recent returns
Strong gains5
Modest gains2
Flat weeks0
Modest losses6
Sharp losses13
Recent vol12.3%13-week weekly-return volatility.
Base vol20.5%52-week weekly-return volatility.
Up/down split19/33Count of positive and negative weeks in the 52-week window.
Average skew20.3% / -9.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-4.9%
Trend breadth66.0%
Trend66.0%active weekly trend signals
MD67.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape19/100
Trend, activity pressure, participation, and risk combine to a 19/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.04; No reversal markers Next-Week ExpectancyNegative 42.06%Next-week expectancy is negative with a 42.06% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors68/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 50; Small Cap Core rank 44 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options37/100IVVD shows volatility options pressure with a 58/100 conviction score, put-call volume ratio of 0.03, expected move of 32.7%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 32.7% Sentiment47/100Weighted news tone is neutral across 56 relevant articles.
Invivyd Inc (IVVD) Technical Analysis: Support, Resistance, Indicators & Moving Averages Insiders6 / 06 acquisitions and 0 disposals in the latest 180-day insider tape.
Earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 0.54 USD | -12.5% | 1.38 USD | 1.60 USD | -1.25 | -68.10 | 16.0M | Off |
| 24 Jul 2026 | 0.61 USD | -17.7% | 1.45 USD | 1.61 USD | -1.16 | -63.50 | 17.3M | Off |
| 17 Jul 2026 | 0.74 USD | -5.2% | 1.52 USD | 1.61 USD | -0.96 | -56.55 | 10.9M | Off |
| 10 Jul 2026 | 0.78 USD | -12.4% | 1.57 USD | 1.62 USD | -0.73 | -56.16 | 23.8M | Off |
| 3 Jul 2026 | 0.89 USD | 0.2% | 1.62 USD | 1.62 USD | -0.73 | -49.17 | 12.7M | Off |
| 26 Jun 2026 | 0.89 USD | -8.1% | 1.66 USD | 1.62 USD | -0.71 | -48.88 | 39.6M | Off |
| 19 Jun 2026 | 0.97 USD | 26.0% | 1.71 USD | 1.62 USD | -0.77 | -46.93 | 43.7M | Off |
| 12 Jun 2026 | 0.77 USD | -25.2% | 1.77 USD | 1.62 USD | -0.83 | -56.78 | 35.5M | Off |
| 5 Jun 2026 | 1.03 USD | -9.6% | 1.82 USD | 1.63 USD | -0.71 | -41.05 | 15.9M | Off |
| 29 May 2026 | 1.14 USD | 3.6% | 1.84 USD | 1.63 USD | -0.58 | -37.90 | 10.8M | Off |
| 22 May 2026 | 1.10 USD | -9.1% | 1.86 USD | 1.63 USD | -0.53 | -38.47 | 15.5M | Off |
| 15 May 2026 | 1.21 USD | -19.3% | 1.90 USD | 1.63 USD | -0.59 | -31.46 | 24.7M | Off |
| 8 May 2026 | 1.50 USD | -1.3% | 1.91 USD | 1.63 USD | -0.65 | -15.17 | 10.1M | Off |
| 1 May 2026 | 1.52 USD | 4.1% | 1.92 USD | 1.63 USD | -0.63 | -8.76 | 6.7M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.